glp-1 agonists vision loss blindness Ocular Effects of Receptor Agonists: A Review of Current Evidence and Safety Concerns A nurse lost her eyesight
Description
Sharma S, Taliyan R
This medication is specifically approved for weight management
L., Bremser S., Alber J., Giavalisco P., et al
PMCID: PMC12721889
Obesity is recognized by the National Institute of Health (NIH) as having a Body Mass Index (BMI) of 30 and above
Amgen is developing a GLP-1/GIP dual agonist called MariTide (currently in phase 3 trials expected to complete in 2027), which is administered as a once-monthly injection
